Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 873

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 873
---
          6.25 | ​ |

The weighted average grant date fair value of options granted to employees and non-employee members of the Board of Directors for their Board service during the years ended December 31, 2023, 2022 and 2021 was $5.75, $7.25, and $12.00, respectively. During the years ended December 31, 2023, 2022 and 2021, the Company recognized compensation expense relating to stock options as follows:

| ​                          
 ​                          | ​ 
 ​ | ​ 
 ​ | Year Ended December 31, 
 2023                    |   |        |   | ​ | ​ | 2022 |   |        |   | ​ | ​ | 2021 |   |        |   | ​ 
 ​ |
|:---------------------------|:--|:--|:------------------------|:--|-------:|:--|:--|:--|:-----|:--|-------:|:--|:--|:--|:-----|:--|-------:|:--|:--|
| Research and development   | ​ | ​ | ​                       | $ |  5,973 | ​ | ​ | ​ | ​    | $ |  7,222 | ​ | ​ | ​ | ​    | $ |  7,126 | ​ | ​ |
| General and administrative | ​ | ​ | ​                       | ​ |  5,634 | ​ | ​ | ​ | ​    | ​ |  6,426 | ​ | ​ | ​ | ​    | ​ |  9,569 | ​ | ​ |
| Total stock option expense | ​ | ​ | ​                       | $ | 11,607 | ​ | ​ | ​ | ​    | $ | 13,648 | ​ | ​ | ​ | ​    | $ | 16,695 | ​ | ​ |

The following were excluded from the table above as they are not related to stock options: compensation expense for i) the vesting of certain employees’ restricted stock units for $476, $765 and $1,201 in R&D expense for the years ended December 31, 2023, 2022 and 2021, respectively, and $1,146, $2,693 and $2,324 in G&A expense for the years ended December 31, 2023, 2022 and 2021,